LILRB2 and metabolic dysfunction-associated steatotic liver disease: The results showed that LILRB2 and ALOX5AP co‐localized in macrophages (Figure S10A,B,D, Supporting Information), and the number of macrophages was significantly higher in the CKD + NAFLD group (Figure S10C, Supporting Information).